Chikungunya: vaccines and therapeutics

Area of Science:

• Virology
• Epidemiology
• Public Health

Background:

• Chikungunya virus (CHIKV) has re-emerged as a significant global pathogen over the past two decades.
• CHIKV outbreaks have escalated from localized events to worldwide epidemics, notably impacting Southeast Asia, India, and the Caribbean.
• Current CHIKV disease management is limited to vector control, which presents substantial challenges, particularly in developing nations, due to the absence of specific treatments or licensed vaccines.

Purpose of the Study:

• To review current findings and advancements in the development of therapeutics for Chikungunya virus disease.
• To summarize progress in creating safe, effective, and affordable vaccines against CHIKV.
• To address the urgent need for targeted interventions against CHIKV, given the limitations of vector control.

Main Methods:

• Comprehensive literature search of recent studies on CHIKV therapeutics and vaccine development.
• Analysis of research data on the efficacy and safety of potential CHIKV interventions.
• Synthesis of information on the challenges and progress in combating CHIKV transmission and disease.

Main Results:

• Significant progress has been made in identifying potential therapeutic targets and drug candidates for CHIKV.
• Several vaccine candidates are in various stages of clinical development, showing promising safety and immunogenicity profiles.
• The review consolidates information on diverse approaches to CHIKV control, from antiviral therapies to novel vaccine strategies.

Conclusions:

• The development of effective CHIKV therapeutics and vaccines is crucial to combatting the growing global burden of this arbovirus.
• Advancements in research offer hope for future interventions, moving beyond reliance on vector control.
• Continued investment and research are essential to deliver safe, affordable, and accessible solutions for CHIKV disease worldwide.